⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4471911 | 0.97 | — | — | |
| SCHEMBL15191474 | 0.92 | L3MBTL3 (0.38) | — | |
| SCHEMBL967360 | 0.92 | — | — | |
| SCHEMBL20973330 | 0.90 | ALDH1A1 (0.35) | — | |
| SCHEMBL1498386 | 0.90 | ALDH1A1 (0.35) | — | |
| SCHEMBL481634 | 0.90 | ALDH1A1 (0.35) | — | |
| SCHEMBL965678 | 0.89 | ALDH1A1 (0.50) | — | |
| SCHEMBL3811874 | 0.88 | ALDH1A1 (0.34) | — | |
| SCHEMBL529684 | 0.88 | ALDH1A1 (0.34) | — | |
| Hydrochloric Acid SCHEMBL11630431 | 0.87 | ALDH1A1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3887371-B1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| US-20210309658-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | claimed |
| EP-3887371-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-10-06 | — | — | EP | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| WO-2020109191-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-04 | — | — | WO | claimed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | claimed |
| EP-2550285-B1 | TRIOXACARCINS AND USES THEREOF | HARVARD COLLEGE (US) | 2017-07-19 | — | — | EP | claimed |
| EP-1799208-A2 | HETEROCYCLIC AROMATIC COMPOUNDS USEFUL AS GROWTH HORMONE SECRETAGOGUES | Brystol-Myers Squibb Company (US) | 2007-06-27 | — | — | EP | claimed |
| US-7166587-B2 | Carbamic acid alkyl ester derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | claimed |
| WO-2006044359-A2 | HETEROCYCLIC AROMATIC COMPOUNDS USEFUL AS GROWTH HORMONE SECRETAGOGUES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-27 | — | — | WO | claimed |
| US-20050075327-A1 | Carbamic acid alkyl ester derivatives | HOFFMAN-LA ROCHE INC. | 2005-04-07 | — | — | US | claimed |
| US-4309517-A | LIVING ALKALI METAL-TERMINATED | PHILLIPS PETROLEUM COMPANY (US) | 1982-01-05 | — | — | US | claimed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-113226468-B | Substituted alkylphenols as HCN1 antagonists | 康奈尔大学 | 2025-03-25 | — | — | CN | disclosed |
| CN-119451974-A | Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens | 巴塞罗那全球健康研究所私人基金会 | 2025-02-14 | — | — | CN | disclosed |
| CN-114174281-B | Degradation agent for cyclin-dependent kinase 7 (CDK 7) and use thereof | 达纳-法伯癌症研究公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| CN-118660883-A | Polycyclic compounds and methods thereof | 海湃泰克(北京)生物医药科技有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118647614-A | Crystalline forms of N- (6-amino-5-methylpyridin-3-yl) -2- (benzo [ d ] thiazol-5-yl) -5-methylpiperidin-1-yl) -2-oxoacetamide, pharmaceutical compositions and methods of use | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118515685-A | Synthesis of halichondrin | 哈佛大学的校长及成员们 | 2024-08-20 | — | — | CN | disclosed |
| CN-118159271-A | Treatment of JAK inhibition responsive conditions with prodrugs of JAK inhibitors | 太阳医药工业公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118043459-A | Chemically modified oligonucleotides | 菲奥医药公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117881395-A | Compositions for delivery of mRNA | 翻译生物公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117794560-A | Stapled peptides and methods thereof | 弗格制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| CN-116999396-A | Modular compositions for removal of soluble biomolecules and related methods | 纳米提克斯有限责任公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116964074-A | Peptides that modulate VEGF | IDP研发制药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111263768-B | anticancer peptides | IDP研发制药有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| CN-116546989-A | N-acetylgalactosamine (GalNAc) derived compounds and oligonucleotides | 阿达尔克斯制药有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-116323638-A | Stapled peptides and methods thereof | 弗格制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116113621-A | Amino acids | 弗格制药有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-3887371-B1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| CN-109071622-B | Peptides with anticancer activity | IDP研发制药有限公司（ES） | 2023-01-13 | — | — | CN | disclosed |
| WO-2022250069-A1 | SULFUR-CONTAINING PYRAZOLE COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT INCLUDING SULFUR-CONTAINING PYRAZOLE COMPOUND AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2022-12-01 | — | — | WO | disclosed |
| CN-115322193-A | EGFR and/or HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115135765-A | Chemically modified oligonucleotides targeting bromodomain-containing protein 4(BRD4) for immunotherapy | 菲奥医药公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-115003703-A | Hyaluronic acid derivatives | 麻省理工学院 | 2022-09-02 | — | — | CN | disclosed |
| CN-111032655-B | EGFR and/or HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114751920-A | Antitumor compounds | 法马马有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114736219-A | Antitumor compounds | 法马马有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-108588151-B | Process for large scale enzymatic synthesis of oligosaccharides | 台湾地区“中央研究院” | 2022-05-13 | — | — | CN | disclosed |
| WO-2022092295-A1 | β-STRAND TYPE CROSSLINKED PEPTIDE | Ｘｅｎｏ－Ｉｎｔｅｒｆａｃｅ株式会社 | 2022-05-05 | — | — | WO | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114245800-A | Melanocyte regulatory peptides | IDP研发制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-114206389-A | Multivalent ligand clusters for targeted delivery of therapeutic agents | 有丝分裂疗法有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114146056-A | Modular compositions for scavenging soluble biomolecules and methods related thereto | 纳米提克斯有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-108546643-B | Process for large scale enzymatic synthesis of oligosaccharides | 台湾地区“中央研究院” | 2022-02-25 | — | — | CN | disclosed |
| CN-108611384-B | Process for large scale enzymatic synthesis of oligosaccharides | 台湾地区“中央研究院” | 2022-02-25 | — | — | CN | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| CN-113993519-A | Degradation agent for cyclin dependent kinase 12(CDK12) and use thereof | 达纳-法伯癌症研究公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113710660-A | DOT1L degradation agent and application thereof | 达纳-法伯癌症研究公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3898613-A1 | ANTICANCER COMPOUNDS | Pharma Mar S.A. (ES) | 2021-10-27 | — | — | EP | disclosed |
| US-20210309658-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3887371-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-113195720-A | Enzymatic RNA synthesis | 哈佛大学的校长及成员们 | 2021-07-30 | — | — | CN | disclosed |
| CN-108504703-B | Process for large scale enzymatic synthesis of oligosaccharides | 中央研究院 | 2021-06-29 | — | — | CN | disclosed |
| EP-3825313-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112812143-A | Triterpene saponin analogues | 佐剂技术公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112739781-A | Dual conjugate markers and methods of use | 宽腾矽公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-112105385-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-108778289-B | Triterpene saponin analogues | 佐剂技术公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-111936136-A | Novel imidazopyrimidine compounds and uses thereof | 儿童医学中心公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-111825733-A | Macrolides and methods of making and using the same | 哈佛大学的校长及成员们 | 2020-10-27 | — | — | CN | disclosed |
| CN-111511761-A | Anticancer peptides | IDP研发制药有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-111436200-A | Anticancer peptides | IDP研发制药有限公司 | 2020-07-21 | — | — | CN | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020109191-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| CN-111201024-A | Chemically modified oligonucleotides | 菲奥医药公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-111032655-A | EGFR and/or HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| CN-110730666-A | Triterpene saponin analogues | 佐剂技术公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-106074591-B | RNA interference in ocular symptoms | 菲奥医药公司 | 2020-01-14 | — | — | CN | disclosed |
| CN-109136974-B | C (sp) -containing2) Process for producing (E) -N bond compound | 中国科学院上海有机化学研究所 | 2019-12-31 | — | — | CN | disclosed |
| CN-110582282-A | Triterpene saponin analogues | 佐剂技术公司 | 2019-12-17 | — | — | CN | disclosed |
| CN-105792852-B | Glucose-responsive insulin conjugates | 默沙东公司 | 2019-12-10 | — | — | CN | disclosed |
| CN-105814043-B | Triazolopyridine derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2019-05-17 | — | — | CN | disclosed |
| CN-105814049-B | Fused tricyclic imdazole derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-109219609-A | FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB生物制药私人有限公司 | 2019-01-15 | — | — | CN | disclosed |
| CN-109219608-A | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB生物制药私人有限公司 | 2019-01-15 | — | — | CN | disclosed |
| CN-109195969-A | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB生物制药私人有限公司 | 2019-01-11 | — | — | CN | disclosed |
| CN-105814041-B | Benzotriazole derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2018-12-18 | — | — | CN | disclosed |
| CN-105814058-B | Triazolo-pyridazine derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-105814065-B | Imidazothiazole derivative as TNF active regulator | UCB生物制药私人有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-105814047-B | Fused tricyclic imdazole derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-105814022-B | Condensed bicyclic heteroaromatic derivative as TNF active regulators | UCB生物制药私人有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-105814051-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2018-09-25 | — | — | CN | disclosed |
| CN-105814054-B | Condensed imidazole and pyrazole derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-09-25 | — | — | CN | disclosed |
| CN-105814025-B | Tetrahydrobenzimidazderivative derivative as TNF active regulators | UCB生物制药私人有限公司 | 2018-09-04 | — | — | CN | disclosed |
| US-20180222868-A1 | Indazole Derivatives as Modulators of TNF Activity | UCB PHARMA S.A. (BE) | 2018-08-09 | — | — | US | disclosed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| CN-105814053-B | Imidazopyridine derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-05-18 | — | — | CN | disclosed |
| CN-105814050-B | Pyrazolopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2018-05-08 | — | — | CN | disclosed |
| EP-3303298-A1 | INDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| CN-105814059-B | Imidazo pyrimidine derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-04-03 | — | — | CN | disclosed |
| CN-105814048-B | Fused tricyclic benzimidizole derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107787319-A | Indazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2018-03-09 | — | — | CN | disclosed |
| CN-105814044-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2018-03-02 | — | — | CN | disclosed |
| CN-107690434-A | Fused tricyclic Imidazopyrazines derivative as TNF active regulators | UCB生物制药私人有限公司 | 2018-02-13 | — | — | CN | disclosed |
| CN-105814060-B | Imidazo-triazine derivative as TNF active regulators | UCB生物制药私人有限公司 | 2018-02-13 | — | — | CN | disclosed |
| CN-105814046-B | Imidazopyridine derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-01-30 | — | — | CN | disclosed |
| CN-105814061-B | Imidazopyridazine derivative as TNF active regulators | UCB生物制药私人有限公司 | 2018-01-26 | — | — | CN | disclosed |
| US-9868749-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-01-16 | — | — | US | disclosed |
| CN-105814052-B | Imidazopyridine derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-01-12 | — | — | CN | disclosed |
| CN-105814056-B | purine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2017-10-10 | — | — | CN | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| CN-105814045-B | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2017-08-25 | — | — | CN | disclosed |
| EP-3177604-A1 | HETEROCYCLIC KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-06-14 | — | — | EP | disclosed |
| CN-105814055-B | As the condensed imidazole and pyrazole derivatives of TNF active regulators | UCB生物制药私人有限公司 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016198401-A1 | INDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2016-12-15 | — | — | WO | disclosed |
| CN-104619709-B | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-11-09 | — | — | CN | disclosed |
| EP-3080115-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080085-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| CN-104768952-B | PI3K inhibitors | 山东亨利医药科技有限责任公司 | 2016-10-19 | — | — | CN | disclosed |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | EVOTEC (UK) LTD. (GB) | 2016-10-13 | — | — | US | disclosed |
| US-9428524-B2 | Synthetic process for the manufacture of ecteinascidin compounds | PHARMA MAR, S.A. (ES) | 2016-08-30 | — | — | US | disclosed |
| CN-105829307-A | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB生物制药私人有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-105814058-A | Triazolopyridazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814044-A | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814053-A | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814061-A | Imidazopyridazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814059-A | Imidazopyrimidine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814046-A | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814056-A | Purine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814055-A | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814025-A | Tetrahydrobenzimidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814051-A | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814065-A | Imidazothiazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814050-A | Pyrazolopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814054-A | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814049-A | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814043-A | Triazolopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814048-A | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814041-A | Benzotriazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814045-A | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814060-A | Imidazotriazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814022-A | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814052-A | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814047-A | Fused tricyclic benzimidazoles derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| US-20160039793-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| WO-2016022312-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | WO | disclosed |
| EP-1673347-B1 | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| WO-2015086523-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086506-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| CN-104619709-A | Imidazopyridine derivatives as modulators of TNF activity | UCB PHARMA SA | 2015-05-13 | — | — | CN | disclosed |
| EP-2576569-B1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS AND INTERMEDIATES | PHARMA MAR SA (ES) | 2015-01-14 | — | — | EP | disclosed |
| WO-2014170295-A1 | COMPOUNDS POTENTIATING THE ACTIVITY OF ANTIFUNGAL DRUGS | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2014-10-23 | — | — | WO | disclosed |
| EP-2792683-A1 | Compounds potentiating the activity of antifungal drugs | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2014-10-22 | — | — | EP | disclosed |
| US-8748388-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-06-10 | — | — | US | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| EP-2650284-A1 | Heterocyclic derivatives as metabotropic glutamate receptor modulators | Merz Pharma GmbH & Co. KGaA (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| EP-2128139-B1 | FLUORINE-CONTAINING PYRAZOLECARBONITRILE DERIVATIVE AND METHOD FOR PRODUCING THE SAME, AND FLUORINE-CONTAINING PYRAZOLECARBOXYLIC ACID DERIVATIVE OBTAINED BY USING THE FLUORINE-CONTAINING PYRAZOLECARBONITRILE DERIVATIVE AND METHOD FOR PRODUCING THE SAME | MITSUI CHEMICALS AGRO INC (JP) | 2013-08-07 | — | — | EP | disclosed |
| EP-2576569-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | Pharma Mar S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2231695-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-02-13 | — | — | EP | disclosed |
| EP-2545046-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8344156-B2 | Method for producing fluorine-containing acylacetic acid derivative, method for producing fluorine-containing pyrazolecarboxylic acid ester derivative, and method for producing fluorine-containing pyrazolecarboxylic acid derivative | MITSUI CHEMICALS AGRO, INC. (JP) | 2013-01-01 | — | — | US | disclosed |
| WO-2012170827-A2 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| CN-102816124-A | Hydroxylated and methoxylated cyclopenta [D] pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2012-12-12 | — | — | CN | disclosed |
| CN-101578273-B | Hydroxylated and methoxylated cyclopenta [ D ] pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2012-11-14 | — | — | CN | disclosed |
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2012-08-23 | — | — | US | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| EP-2451812-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| CN-1894217-B | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors | HOFFMANN LA ROCHE | 2011-09-21 | — | — | CN | disclosed |
| WO-2011111875-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | WO | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| US-7884216-B2 | Fluorine-containing pyrazolecarbonitrile derivative and method for producing the same, and fluorine-containing pyrazolecarboxylic acid derivative obtained by using the fluorine-containing pyrazolecarbonitrile derivative and method for producing the same | MITSUI CHEMICALS AGRO, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20110015406-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING ACYLACETIC ACID DERIVATIVE, METHOD FOR PRODUCING FLUORINE-CONTAINING PYRAZOLECARBOXYLIC ACID ESTER DERIVATIVE, AND METHOD FOR PRODUCING FLUORINE-CONTAINING PYRAZOLECARBOXYLIC ACID DERIVATIVE | MITSUI CHEMICALS AGRO, INC. (JP) | 2011-01-20 | — | — | US | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010149688-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-12-29 | — | — | WO | disclosed |
| EP-2263999-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING ACYLACETIC ACID DERIVATIVE, METHOD FOR PRODUCING FLUORINE-CONTAINING PYRAZOLECARBOXYLIC ACID ESTER DERIVATIVE, AND METHOD FOR PRODUCING FLUORINE-CONTAINING PYRAZOLECARBOXYLIC ACID DERIVATIVE | Mitsui Chemicals Agro, Inc. (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
| WO-2010127208-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-04 | — | — | WO | disclosed |
| EP-2231695-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| EP-2225218-A1 | THIAZOLYLOXYPHENYLAMIDINES OR THIADIAZOLYLOXYPHENYLAMIDINES AND THEIR USE AS FUNGICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2010-09-08 | — | — | EP | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20100016612-A1 | FLUORINE-CONTAINING PYRAZOLECARBONITRILE DERIVATIVE AND METHOD FOR PRODUCING THE SAME, AND FLUORINE-CONTAINING PYRAZOLECARBOXYLIC ACID DERIVATIVE OBTAINED BY USING THE FLUORINE-CONTAINING PYRAZOLECARBONITRILE DERIVATIVE AND METHOD FOR PRODUCING THE SAME | MITSUI CHEMICALS AGRO, INC (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| EP-2128139-A1 | FLUORINE-CONTAINING PYRAZOLECARBONITRILE DERIVATIVE AND METHOD FOR PRODUCING THE SAME, AND FLUORINE-CONTAINING PYRAZOLECARBOXYLIC ACID DERIVATIVE OBTAINED BY USING THE FLUORINE-CONTAINING PYRAZOLECARBONITRILE DERIVATIVE AND METHOD FOR PRODUCING THE SAME | MITSUI CHEMICALS AGRO, INC. (JP) | 2009-12-02 | — | — | EP | disclosed |
| CN-101578273-A | Hydroxylated and methoxylated cyclopenta [ D ] pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2009-11-11 | — | — | CN | disclosed |
| WO-2009083105-A1 | THIAZOLYLOXYPHENYLAMIDINES OR THIADIAZOLYLOXYPHENYLAMIDINES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009077401-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | WO | disclosed |
| US-7482339-B2 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-7420053-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2008-09-02 | — | — | US | disclosed |
| EP-1219612-B1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| EP-1831174-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-20070088020-A1 | 2-imino-1,3-thiazine derivatives | HANASAKI KOJI | 2007-04-19 | — | — | US | disclosed |
| US-7183275-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7166587-B2 | Carbamic acid alkyl ester derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | disclosed |
| CN-1894217-A | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors | HOFFMANN LA ROCHE (CH) | 2007-01-10 | — | — | CN | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| WO-2006067444-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1673347-A1 | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS | F. Hoffman-la Roche AG (CH) | 2006-06-28 | — | — | EP | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | TADA YUKIO | 2006-03-09 | — | — | US | disclosed |
| US-6977266-B2 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2005-12-20 | — | — | US | disclosed |
| EP-1603890-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6916806-B2 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | HANASAKI KOJI (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| WO-2005040126-A1 | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050075327-A1 | Carbamic acid alkyl ester derivatives | HOFFMAN-LA ROCHE INC. | 2005-04-07 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6818640-B1 | BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS | SHIONOGI & CO., LTD. (JP) | 2004-11-16 | — | — | US | disclosed |
| WO-2004078734-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040116326-A1 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1375489-A1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1357111-A1 | PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1219612-A1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-4640958-A | ACRYLOYL CHLORIDE | ATLANTIC RICHFIELD COMPANY (US) | 1987-02-03 | — | — | US | disclosed |
| US-4503188-A | ANIONIC POLYMERIZATION | ATLANTIC RICHFIELD COMPANY (US) | 1985-03-05 | — | — | US | disclosed |
| US-4426523-A | Preparation of 1-amino-1,3,5-triazine-2,4(1H, 3H)-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-17 | — | — | US | disclosed |
| US-4309517-A | LIVING ALKALI METAL-TERMINATED | PHILLIPS PETROLEUM COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
| US-4309517-A | LIVING ALKALI METAL-TERMINATED | PHILLIPS PETROLEUM COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
| US-4309517-A | LIVING ALKALI METAL-TERMINATED | PHILLIPS PETROLEUM COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
| US-4309517-A | LIVING ALKALI METAL-TERMINATED | PHILLIPS PETROLEUM COMPANY (US) | 1982-01-05 | — | — | US | disclosed |